Invalid Symbol

Stock Research for ANAC

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


ANAC Stock Chart & Research Data

The ANAC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANAC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ANAC Due diligence Resources & Stock Charts

The ANAC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANAC Detailed Price Forecast - CNN Money CNN View ANAC Detailed Summary - Google Finance
Yahoo View ANAC Detailed Summary - Yahoo! Finance Zacks View ANAC Stock Research & Analysis -

Stock Analysis

TradeIdeas View ANAC Trends & Analysis - Trade-Ideas Barrons View ANAC Major Holders - Barrons
NASDAQ View ANAC Call Transcripts - NASDAQ Seeking View ANAC Breaking News & Analysis - Seeking Alpha
Spotlight View ANAC Annual Report - OTC Report View ANAC OTC Short Report -
TradeKing View ANAC Fundamentals - TradeKing Charts View ANAC SEC Filings - Bar Chart
WSJ View Historical Prices for ANAC - The WSJ Morningstar View Performance/Total Return for ANAC - Morningstar
MarketWatch View the Analyst Estimates for ANAC - MarketWatch CNBC View the Earnings History for ANAC - CNBC
StockMarketWatch View the ANAC Earnings - StockMarketWatch MacroAxis View ANAC Buy or Sell Recommendations - MacroAxis
Bullish View the ANAC Bullish Patterns - American Bulls Short Pains View ANAC Short Pain Metrics -

Social Media Mentions

StockTwits View ANAC Stock Mentions - StockTwits PennyStocks View ANAC Stock Mentions - PennyStockTweets
Twitter View ANAC Stock Mentions - Twitter Invest Hub View ANAC Investment Forum News - Investor Hub
Yahoo View ANAC Stock Mentions - Yahoo! Message Board Seeking Alpha View ANAC Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ANAC - Insider Cow View Insider Transactions for ANAC - Insider Cow
CNBC View ANAC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANAC - OTC Markets
Yahoo View Insider Transactions for ANAC - Yahoo! Finance NASDAQ View Institutional Holdings for ANAC - NASDAQ

Stock Charts

FinViz View ANAC Stock Insight & Charts - StockCharts View ANAC Investment Charts -
BarChart View ANAC Stock Overview & Charts - BarChart Trading View View ANAC User Generated Charts - Trading View

Latest Financial News for ANAC

New Product Launches May Boost Valeant’s Dermatology Revenue
Posted on Thursday March 23, 2017

New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after ...

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Why Anacor Pharmaceuticals, Inc. Stock Jumped 58.3% in May
Motley Fool - Jun 5, 2016
Now what: While its toenail fungus ointment has no legs and probably won't bring the company to profitability, an application submitted to the FDA in March seeking approval for a novel eczema ointment just might have.
Why Would Anacor Sell? - Seeking Alpha

Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel
Reuters - May 16, 2016
(Reuters) - Pfizer Inc (PFE.N) is buying Anacor Pharmaceuticals Inc ANAC.O in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after the U.S.
Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion - New York Times

Anacor Pharmaceuticals Is Too Expensive
Seeking Alpha - Jan 19, 2016
Kerydin sales have ramped up nicely and the company reported positive phase 3 trial results for Crisaborole. Shares are up substantially in the last two years and the company's current market cap implies a great future for its two products. I can see ...

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move ...
Motley Fool - May 24, 2016
On May 16, Pfizer announced that it was acquiring Anacor Pharmaceuticals (NASDAQ:ANAC) for the hefty sum of $99.25 in cash per share, or a 55% premium to where Anacor shares closed on Friday.

Enter a stock symbol to view the stock details.